Academic Journals Database
Disseminating quality controlled scientific knowledge

The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo

ADD TO MY LIST
 
Author(s): Gao Yuanhong | Ishiyama Hiromichi | Sun Mianen | Brinkman Kathryn | Wang Xiaozhen | Zhu Julie | Mai Weiyuan | Huang Ying | Floryk Daniel | Ittmann Michael | Thompson Timothy | Butler E | Xu Bo | Teh Bin

Journal: Radiation Oncology
ISSN 1748-717X

Volume: 6;
Issue: 1;
Start page: 39;
Date: 2011;
Original page

ABSTRACT
Abstract Background Perifosine is a membrane-targeted alkylphospholipid developed to inhibit the PI3K/Akt pathway and has been suggested as a favorable candidate for combined use with radiotherapy. In this study, we investigated the effect of the combined treatment of perifosine and radiation (CTPR) on prostate cancer cells in vitro and on prostate cancer xenografts in vivo. Methods Human prostate cancer cell line, CWR22RV1, was treated with perifosine, radiation, or CTPR. Clonogenic survival assays, sulforhodamine B cytotoxity assays and cell density assays were used to assess the effectiveness of each therapy in vitro. Measurements of apoptosis, cell cycle analysis by flow cytometry and Western blots were used to evaluate mechanisms of action in vitro. Tumor growth delay assays were used to evaluate radiation induced tumor responses in vivo. Results In vitro, CTPR had greater inhibitory effects on prostate cancer cell viability and clonogenic survival than either perifosine or radiation treatment alone. A marked increase in prostate cancer cell apoptosis was noted in CTPR. Phosphorylation of AKT-T308 AKT and S473 were decreased when using perifosine treatment or CTPR. Cleaved caspase 3 was significantly increased in the CTPR group. In vivo, CTPR had greater inhibitory effects on the growth of xenografts when compared with perifosine or radiation treatment alone groups. Conclusions Perifosine enhances prostate cancer radiosensitivity in vitro and in vivo. These data provide strong support for further development of this combination therapy in clinical studies.
Affiliate Program     

Tango Rapperswil
Tango Rapperswil